Boosting Confidence in Drug Discovery with PBPK
Explore Simcyp Discovery Version 2 updates to boost early-stage drug development.
CertaraJuly 25, 2025
How Pharma Can Transition to Non-animal Studies for Investigational Drugs
Pharma companies can ease the transition to non-animal studies for investigational drugs by leveraging NAMs…
CertaraJuly 25, 2025
The end of animal testing? Transitioning to models is promising — but no silver bullet
The FDA has stated that the pharma industry must transition to using in vitro assays,…
CertaraJuly 21, 2025
How is the pharmaceutical industry addressing global health inequities?
Explore Karen Rowland Yeo's insights on using Model-Informed Drug Development to address global health equities…
CertaraJune 17, 2025
Redefining Regulatory Strategy with MIDD: Insights from the Draft ICH M15 Guidance
With the release of the draft ICH M15 guidance, MIDD is no longer optional -…
CertaraJune 11, 2025
Evolving Regulatory Landscape for Model Informed Drug Development (MIDD): Impact of the Draft ICH M15 Guidance
SVP, PBPK Consultancy Services, Certara SVP, Quantitative Science Services, Certara Sr. Director, Clinical Pharmacology, Certara…
CertaraMay 23, 2025
Certara’s Simcyp Educational Webinar Series: Learn from A to Z of PBBM Part 2: What is the Drug Absorption Model?
Part 3 in November: Understanding the Supersaturated Dissolution in the Digestive Tract with Modeling &…
CertaraMay 12, 2025
Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions
Director, Clinical Pharmacology, ORIC Pharmaceuticals SVP, Head of Simcyp PBPK Modeling Services, Certara Director, PBPK…
CertaraApril 21, 2025
